Navigating Beovu AHA/ACC Guidelines Prior Authorization Criteria for Ophthalmic Therapies

The Role of AHA/ACC Guidelines in Clinical Practice and Prior Authorization

The American Heart Association (AHA) and American College of Cardiology (ACC) Guidelines are foundational, evidence-based recommendations primarily focused on cardiovascular health. Their structured approach to diagnosis, treatment, and management sets a benchmark for medical necessity criteria widely referenced by payers for cardiac and vascular conditions. This rigorous framework underscores the importance of adhering to established clinical guidelines across all medical specialties for successful prior authorization.

Beovu's Clinical Indications and Relevant Guideline Bodies

Beovu (brolucizumab) is an anti-VEGF therapy indicated for specific ophthalmic conditions, primarily neovascular (wet) Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME). Consequently, prior authorization criteria for Beovu are not derived from AHA/ACC Guidelines. Instead, payers typically base their medical policies on recommendations from professional ophthalmology organizations, such as the American Academy of Ophthalmology (AAO), and their own proprietary medical necessity criteria.

Core Prior Authorization Criteria for Beovu

To secure prior authorization for Beovu, clinics must demonstrate adherence to specific, ophthalmology-focused criteria. These often include a confirmed diagnosis and evidence of active disease.

Typical Beovu PA Criteria Include:

• Confirmed diagnosis of nAMD or DME by an ophthalmologist.
• Evidence of active disease, typically demonstrated by intraretinal or subretinal fluid on Optical Coherence Tomography (OCT).
• Baseline visual acuity measurements.
• Documentation of prior anti-VEGF therapy (e.g., ranibizumab, aflibercept) failure or intolerance, if Beovu is considered a subsequent line of therapy per payer policy.
• Absence of contraindications as per prescribing information.

Essential Documentation for Beovu Prior Authorization Success

Accurate and comprehensive documentation is paramount for Beovu prior authorization approval. PA reviewers expect detailed clinical evidence supporting the medical necessity of the treatment, aligning with the relevant ophthalmic guidelines and payer policies.

Key Documentation Required:

• Ophthalmologist's progress notes detailing diagnosis, symptoms, and treatment plan.
• Current and historical visual acuity measurements.
• High-quality OCT imaging reports demonstrating active disease.
• Fluorescein angiography reports, if performed and relevant to diagnosis.
• Documentation of previous anti-VEGF treatments, including dates, agents used, and response to therapy.
• Attestation of patient's eligibility based on specific payer criteria.

Common Prior Authorization Denial Themes for Beovu

Denials for Beovu prior authorizations often stem from a misalignment with payer-specific medical policies or insufficient clinical documentation. Understanding these common themes can help your team proactively address potential issues.

Frequent Denial Reasons:

• Inadequate documentation of active disease or visual acuity thresholds.
• Failure to demonstrate appropriate prior therapy trial, if required by payer step-therapy protocols.
• Lack of detailed clinical notes supporting the medical necessity of Beovu over alternative therapies.
• Non-adherence to specific dosing or administration frequency criteria.
• Submission of outdated or incomplete clinical records.

Streamlining Beovu Prior Authorizations with Klivira

Klivira's platform automates the complex process of prior authorization for specialty medications like Beovu. By integrating with EMRs and payer portals, Klivira ensures that all required clinical data and documentation, adhering to specific ophthalmic guidelines and payer policies, are accurately collected and submitted. This reduces manual effort, accelerates approval times, and minimizes denials related to non-adherence to criteria or documentation deficiencies.